Exacerbation severity and frequency are crucial for the prognosis of COPD, but also appear to have a major impact on the course of comorbidities. There is a growing body of evidence showing that COPD patients are at increased risk of cardiovascular events, with the frequency and severity of exacerbations being important predictors. Optimal treatment of COPD also appears to reduce the risk of concomitant diseases. Depending on the situation, it may make sense to extend dual bronchodilation with inhaled steroids or roflumilast as an add-on.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Artificial intelligence in diabetes prevention
Lifestyle interventions are better accepted with AI
- B-cell lymphomas
Bispecific antibodies – mechanisms, evidence and future role
- Dermatoscopic findings of granulomatous diseases
Cutaneous sarcoidosis, necrobiosis lipoidica and granuloma anulare
- Clostridioides difficile infection: specific therapy
Importance of vancomycin and fidaxomicin has increased
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity